Polyganics Overview

  • Founded
  • 1999
  • Status
  • Private
  • Employees
  • 31
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $2.61M
Latest Deal Amount
  • Investors
  • 8

Polyganics General Information


Developer of bioresorbable devices designed to transform patient recovery. The company's devices facilitate tissue repair and regeneration after surgery, enabling healthcare providers to cure their patients and improve their lives.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Surgical Devices
Other Industries
Therapeutic Devices
Primary Office
  • Rozenburglaan 15A
  • 9727 DL Groningen
  • Netherlands
+31 050 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Polyganics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant 13-May-2020 $2.61M Completed Generating Revenue
1. Early Stage VC Completed Generating Revenue
To view Polyganics’s complete valuation and funding history, request access »

Polyganics Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Developer of bioresorbable devices designed to transform patient recovery. The company's devices facilitate tissue repai
Surgical Devices
Groningen, Netherlands
31 As of 2014


rud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in r
00000000 0000000
New York, NY
000 As of 0000
000000 - 000


onsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut en
00000000000 0000000
Shanghai, China
00 As of 0000
00000000000 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Polyganics Competitors (12)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Angiodynamics Corporation New York, NY 000 000000 - 000
0000000000 0000000 Venture Capital-Backed Shanghai, China 00 00.00 00000000000 00.00
000000 0000000 Corporate Backed or Acquired Somerset, NJ
00000 0000000 Formerly VC-backed Irvine, CA 000 00000 00000000 00000
0000000 0000000 Venture Capital-Backed Waltham, MA 00 000.00 00000000000 000.00
You’re viewing 5 of 12 competitors. Get the full list »

Polyganics Executive Team (6)

Name Title Board Seat Contact Info
Rudy Mareel Chief Executive Officer & Board Member
Paul Roos Chief Financial Officer
Jan Disbergen Chief Operating Officer
Romke Ribbels Director Marketing & Business Development
Raoul Beex International Sales Director
You’re viewing 5 of 6 executive team members. Get the full list »

Polyganics Board Members (5)

Name Representing Role Since
Annemieke Wouterse Noordelijke Ontwikkelings Maatschappij Supervisory Board Member 000 0000
Jan Ohrstrom MD Self Board Member 000 0000
Ralph Voncken Polyganics Chairman 000 0000
Rudy Mareel Polyganics Chief Executive Officer & Board Member 000 0000
To view Polyganics’s complete board members history, request access »

Polyganics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Polyganics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
European Fund for Regional Development Corporation 000 0000 000000 0
European Union Government 000 0000 000000 0
Provinces of Groningen Government 000 0000 000000 0
Agile Investments Growth/Expansion Minority 000 0000 000000 0
BioPartner Start-up Ventures Not-For-Profit Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »